73.79
price up icon1.30%   0.95
after-market After Hours: 73.75 -0.04 -0.05%
loading
Astrazeneca PLC stock is traded at $73.79, with a volume of 3.43M. It is up +1.30% in the last 24 hours and down -2.46% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$72.84
Open:
$73.7
24h Volume:
3.43M
Relative Volume:
0.68
Market Cap:
$228.77B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
32.72
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
-1.52%
1M Performance:
-2.46%
6M Performance:
-4.93%
1Y Performance:
+8.92%
1-Day Range:
Value
$73.43
$74.19
1-Week Range:
Value
$71.82
$75.12
52-Week Range:
Value
$62.75
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
73.79 228.77B 54.07B 7.04B 7.28B 2.255

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
11:43 AM

J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN

11:43 AM
pulisher
Mar 29, 2025

SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.

Mar 29, 2025
pulisher
Mar 29, 2025

AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues

Mar 29, 2025
pulisher
Mar 28, 2025

AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360

Mar 28, 2025
pulisher
Mar 28, 2025

Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 28, 2025

Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

AstraZeneca Fights Generic Diabetes Drug Launch - Law360

Mar 27, 2025
pulisher
Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com

Mar 27, 2025
pulisher
Mar 26, 2025

Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360

Mar 26, 2025
pulisher
Mar 26, 2025

J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business

Mar 26, 2025
pulisher
Mar 26, 2025

J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - Bloomberg

Mar 26, 2025
pulisher
Mar 26, 2025

AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law

Mar 26, 2025
pulisher
Mar 26, 2025

China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg

Mar 26, 2025
pulisher
Mar 26, 2025

Whittier Trust Co. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld Online

Mar 25, 2025
pulisher
Mar 25, 2025

Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

AstraZeneca Seeks to Move Past China Probe With R&D Hub - Bloomberg

Mar 25, 2025
pulisher
Mar 25, 2025

AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia

Mar 25, 2025
pulisher
Mar 24, 2025

AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch

Mar 24, 2025
pulisher
Mar 24, 2025

Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors UK

Mar 24, 2025
pulisher
Mar 24, 2025

Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo Finance UK

Mar 24, 2025
pulisher
Mar 24, 2025

AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology

Mar 24, 2025
pulisher
Mar 24, 2025

Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 23, 2025

Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha

Mar 23, 2025
pulisher
Mar 23, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Mar 23, 2025
pulisher
Mar 21, 2025

AstraZeneca Expands Emphasis On China, Already A Key Market - News & Insights

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon -March 21, 2025 at 03:50 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to invest $2.5bn in China after snub for UK plant - The Times

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca To Invest $2.5B In China Research Hub - Law360

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care Stocks Fall in Afternoon Trading -March 21, 2025 at 01:50 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care -March 21, 2025 at 01:39 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Going in vivo: AstraZeneca acquires EsoBiotec in potential $1bn deal - BioXconomy

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca deepens China investment; Editas loses CFO to Dyne - BioPharma Dive

Mar 21, 2025
pulisher
Mar 21, 2025

HBM Holdings To Issue To Astrazeneca Holdings Subscription Shares -March 21, 2025 at 11:28 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Kangtai Biological Products To Establish JV With AstraZeneca -March 21, 2025 at 10:40 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to invest £2bn in Beijing amid China investigation - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Micron, Johnson & Johnson, AstraZeneca: Top Stocks - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed - BioWorld Online

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to make a $2.5B investment in China (AZN:NASDAQ) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca invests US$2.5 bil in Beijing hub amid probe - The Edge Malaysia

Mar 21, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):